Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

NCT06174220 is registered in ClinicalTrials.gov with Hamilton Health Sciences Corporation as lead sponsor.

NCT NCT06174220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06174220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
Lead sponsor
Hamilton Health Sciences Corporation
Phase
Phase 2
Overall status
Recruiting
Start date
March 21, 2025
Completion date
July 1, 2027
Enrollment
120 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

arrhythmogenic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy